Home » Psychology news » BioMarin Initiates Phase 3b Study To Evaluate The Effects Of Kuvan On Neurophychiatric Symptoms In Subjects With PKU
BioMarin Initiates Phase 3b Study To Evaluate The Effects Of Kuvan On Neurophychiatric Symptoms In Subjects With PKU
August 18, 2010 by NewsBot
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). BioMarin expects to report results in the first half of 2012...


